Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$3.65 +2.2%	$3.96	$2.83 ▼ $6.82	$161.24M	1.17	99,685 shs	153,019 shs
HOTH Hoth Therapeutics	$1.21 +0.4%	$1.06	$0.58 ▼ $3.80	$15.98M	0.67	3.71 million shs	132,991 shs
SMMT Summit Therapeutics	$24.35 +7.6%	$22.75	$6.90 ▼ $36.91	$18.23B	-1.01	3.71 million shs	12.73 million shs
TORC resTORbio	$0.61 -1.1%	$12.16	$0.86 ▼ $10.50	$22.13M	2.43	1.15 million shs	545,982 shs
VBLT Vascular Biogenics		$0.40	$0.10 ▼ $6.74	$423.91M	0.77	2.19 million shs	161,505 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	0.00%	-4.95%	-13.10%	+4.29%	+24.15%
HOTH Hoth Therapeutics	0.00%	+6.64%	-21.24%	+43.47%	+34.62%
SMMT Summit Therapeutics	0.00%	+18.18%	+24.46%	+40.24%	+253.34%
TORC resTORbio	-1.14%	-9.48%	-22.08%	-9.54%	-44.82%
VBLT Vascular Biogenics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DMAC DiaMedica Therapeutics	0.8913 of 5 stars	3.5	1.0	0.0	0.0	0.0	0.0	0.0
HOTH Hoth Therapeutics	1.5909 of 5 stars	3.6	2.0	0.0	0.0	0.6	0.0	0.6
SMMT Summit Therapeutics	2.5202 of 5 stars	4.4	1.0	0.0	0.0	2.0	1.7	0.0
TORC resTORbio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	119.18% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	231.95% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	42.40% Upside
TORC resTORbio	0.00	N/A	N/A	N/A
VBLT Vascular Biogenics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HOTH, VBLT, SMMT, DMAC, and TORC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
SMMT Summit Therapeutics	$700K	25,829.00	N/A	N/A	$0.53 per share	45.93
TORC resTORbio	N/A	N/A	N/A	N/A	$2.24 per share	N/A
VBLT Vascular Biogenics	$660K	0.00	N/A	N/A	$0.32 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/6/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TORC resTORbio	-$82.74M	-$2.41	N/A	N/A	N/A	N/A	-78.12%	-71.63%	N/A
VBLT Vascular Biogenics	-$32.30M	-$0.21	N/A	N/A	N/A	N/A	-73.45%	-54.11%	N/A

Latest HOTH, VBLT, SMMT, DMAC, and TORC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
HOTH Hoth Therapeutics	N/A	15.09	15.08
SMMT Summit Therapeutics	N/A	10.63	10.63
TORC resTORbio	N/A	20.69	20.69
VBLT Vascular Biogenics	N/A	4.63	4.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
HOTH Hoth Therapeutics	7.08%
SMMT Summit Therapeutics	4.61%
TORC resTORbio	46.19%
VBLT Vascular Biogenics	0.96%

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	7.30%
HOTH Hoth Therapeutics	6.92%
SMMT Summit Therapeutics	84.90%
TORC resTORbio	11.80%
VBLT Vascular Biogenics	6.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	20	42.88 million	39.75 million	Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TORC resTORbio	N/A	36.45 million	N/A	Not Optionable
VBLT Vascular Biogenics	7	77.64 million	72.88 million	Optionable

HOTH, VBLT, SMMT, DMAC, and TORC Headlines

Recent News About These Companies

VBL warns of financial impact of severance payments in second pillar reform

September 4, 2024 | ipe.comI

Market Unimpressed By VBL's 26% Jump In Net Profit, Shares Tank 5%

July 30, 2024 | msn.com

Tom Sox move one step closer to VBL title with 7-5 win over Purcellville

July 30, 2024 | cbs19news.comC

Tom Sox drop game one of the VBL South Division Series against Cavaliers, 4-1

July 26, 2024 | cbs19news.comC

Benign and Malignant Vascular Tumors of the Liver in Adults

May 23, 2024 | medscape.comM

VBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To Come

May 14, 2024 | msn.com

AlboGraft Polyester Vascular Graft from LeMaitre

May 7, 2024 | news-medical.netN

Tommy Garten elected to VBL Hall of Fame

March 28, 2024 | therecorderonline.comT

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

February 21, 2024 | nature.comN

Vascular News and Research

November 25, 2023 | news-medical.netN

Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26

November 2, 2023 | msn.com

Notable Labs Closes Merger Transaction With VBL Therapeutics

October 16, 2023 | finance.yahoo.com

VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

October 12, 2023 | finance.yahoo.com

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

October 4, 2023 | finance.yahoo.com

Vascular Biogenics Rises on Presentation Hype

September 9, 2023 | finance.yahoo.com

VBLT Stock Sees Decline of Approximately -0.22% in Last Five Days

September 7, 2023 | knoxdaily.comK

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

September 6, 2023 | finance.yahoo.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 28, 2023 | businesswire.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 28, 2023 | businesswire.com

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 14, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOTH, VBLT, SMMT, DMAC, and TORC Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$3.65 +0.08 (+2.24%)

Closing price 07/3/2025 03:41 PM Eastern

Extended Trading

$3.72 +0.07 (+2.03%)

As of 07/3/2025 04:46 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Hoth Therapeutics NASDAQ:HOTH

$1.20 +0.01 (+0.42%)

Closing price 07/3/2025 03:36 PM Eastern

Extended Trading

$1.20 0.00 (0.00%)

As of 07/3/2025 04:44 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$24.34 +1.73 (+7.63%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$24.39 +0.05 (+0.18%)

As of 07/3/2025 04:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

resTORbio NASDAQ:TORC

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Vascular Biogenics NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time